BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 21707845)

  • 1. Matrix-producing carcinoma of the breast in the Chinese population: a clinicopathological study of 13 cases.
    Shui R; Bi R; Cheng Y; Lu H; Wang J; Yang W
    Pathol Int; 2011 Jul; 61(7):415-22. PubMed ID: 21707845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast carcinoma with chondroid differentiation: a clinicopathologic study of 21 triple negative (ER-, PR-, Her2/neu-) cases.
    Gwin K; Wheeler DT; Bossuyt V; Tavassoli FA
    Int J Surg Pathol; 2010 Feb; 18(1):27-35. PubMed ID: 19282292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases.
    Carter MR; Hornick JL; Lester S; Fletcher CD
    Am J Surg Pathol; 2006 Mar; 30(3):300-9. PubMed ID: 16538049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
    Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
    Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological parameters and biological markers predicting non-sentinel node metastasis in sentinel node-positive breast cancer patients.
    Kwon Y; Ro J; Kang HS; Kim SK; Hong EK; Khang SK; Gong G; Ro JY
    Oncol Rep; 2011 Apr; 25(4):1063-71. PubMed ID: 21258771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
    D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
    Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression.
    Barnes PJ; Boutilier R; Chiasson D; Rayson D
    Breast Cancer Res Treat; 2005 May; 91(2):173-8. PubMed ID: 15868445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of molecular classification of breast invasive ductal carcinoma.
    Muñoz M; Fernández-Aceñero MJ; Martín S; Schneider J
    Arch Gynecol Obstet; 2009 Jul; 280(1):43-8. PubMed ID: 19082617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metaplastic carcinoma of the breast: analysis of eight Asian patients with special emphasis on two unusual cases presenting with inflammatory-type breast cancer.
    Kuo SH; Chen CL; Huang CS; Cheng AL
    Anticancer Res; 2000; 20(3B):2219-22. PubMed ID: 10928181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
    Iwase H; Kurebayashi J; Tsuda H; Ohta T; Kurosumi M; Miyamoto K; Yamamoto Y; Iwase T
    Breast Cancer; 2010 Apr; 17(2):118-24. PubMed ID: 19466512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Matrix-producing breast carcinoma with myoepithelial differentiation--description of 11 cases and review of literature aimed at histogenesis and differential diagnosis].
    Kinkor Z; Boudová L; Ryska A; Kajo K; Svec A
    Ceska Gynekol; 2004 May; 69(3):229-36. PubMed ID: 15310000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
    González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
    Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA1 expression in invasive breast carcinomas and clinicopathological correlations.
    Comănescu M; Popescu CF
    Rom J Morphol Embryol; 2009; 50(3):419-24. PubMed ID: 19690768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
    Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
    Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast.
    Grenier J; Soria JC; Mathieu MC; Andre F; Abdelmoula S; Velasco V; Morat L; Besse B; Dunant A; Spielmann M; Delaloge S
    Anticancer Res; 2007; 27(1B):547-55. PubMed ID: 17348440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paneth cell-like eosinophilic cytoplasmic granules in breast carcinoma.
    Huo L; Bell D; Qiu H; Sahin A; Wu Y; Sneige N
    Ann Diagn Pathol; 2011 Apr; 15(2):84-92. PubMed ID: 21163678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process.
    Vincent-Salomon A; Jouve M; Genin P; Fréneaux P; Sigal-Zafrani B; Caly M; Beuzeboc P; Pouillart P; Sastre-Garau X
    Cancer; 2002 Apr; 94(8):2169-73. PubMed ID: 12001113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.